Patient distribution and estimated relative risk of death for the prognostic model using biomarkers compared with the IPI in the r-CHOP cohort
| . | . | IPI groups . | Biomarkers and IPI* . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Low . | Low-intermediate . | High-intermediate . | High . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | ||
| No. of patients (%)† | 94 (27) | 80 (23) | 87 (25) | 86 (25) | 56 (20) | 84 (30) | 58 (20) | 86 (30) | |
| r-CHOP | 4-year OS | 85% | 80% | 68% | 45% | 94% | 81% | 62% | 45% |
| HR (95% CI) | 1 | 1.6 (0.8, 3.4) | 2.5 (1.3, 4.9) | 5.1 (2.7, 9.6) | 1 | 3.6 (1.1, 12) | 8.4 (2.5, 28) | 13 (3.9, 41) | |
| No. of patients (%)† | 79 (27) | 63 (22) | 79 (27) | 68 (24) | 38 (16) | 92 (38) | 46 (19) | 68 (28) | |
| c-CHOP | 4-year OS | 84% | 63% | 48% | 26% | 95% | 62% | 54% | 26% |
| HR (95% CI) | 1 | 2.9 (1.5, 5.5) | 3.9 (2.1, 7.2) | 7.3 (4.0, 14) | 1 | 9.0 (2.2, 37) | 9.5 (2.2, 40) | 22 (5.5, 92) | |
| . | . | IPI groups . | Biomarkers and IPI* . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Low . | Low-intermediate . | High-intermediate . | High . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | ||
| No. of patients (%)† | 94 (27) | 80 (23) | 87 (25) | 86 (25) | 56 (20) | 84 (30) | 58 (20) | 86 (30) | |
| r-CHOP | 4-year OS | 85% | 80% | 68% | 45% | 94% | 81% | 62% | 45% |
| HR (95% CI) | 1 | 1.6 (0.8, 3.4) | 2.5 (1.3, 4.9) | 5.1 (2.7, 9.6) | 1 | 3.6 (1.1, 12) | 8.4 (2.5, 28) | 13 (3.9, 41) | |
| No. of patients (%)† | 79 (27) | 63 (22) | 79 (27) | 68 (24) | 38 (16) | 92 (38) | 46 (19) | 68 (28) | |
| c-CHOP | 4-year OS | 84% | 63% | 48% | 26% | 95% | 62% | 54% | 26% |
| HR (95% CI) | 1 | 2.9 (1.5, 5.5) | 3.9 (2.1, 7.2) | 7.3 (4.0, 14) | 1 | 9.0 (2.2, 37) | 9.5 (2.2, 40) | 22 (5.5, 92) | |
Biomarkers and IPI: Group 1 = low IPI and BCL2 ≤ 75%; Group 2 = low IPI and BCL2 > 75% or low-intermediate IPI and Ki67 ≤ 75% or high-intermediate IPI and Ki67 ≤ 75%; Group 3 = low-intermediate IPI/high-intermediate IPI and Ki67 > 75%; Group 4 = high IPI.
Two hundred eighty-four of 347 r-CHOP and 244 of 289 c-CHOP patients had data available to compute biomarker and IPI index.